CHRISTOPHER MASSEY: Open Payments
NPI 1417903907 · RAYNHAM, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,589 in 152 payments from 21 companies in 2025. Trend: 2023 $56,970 · 2024 $19,061 · 2025 $3,589
Food & beverage: $3,546Education: $34Consulting: $9
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 28 | $767 |
| GENZYME CORPORATION | 14 | $456 |
| CSL Behring | 16 | $379 |
| Regeneron Healthcare Solutions, Inc. | 13 | $300 |
| Novartis Pharmaceuticals Corporation | 17 | $233 |
| PFIZER INC. | 10 | $227 |
| Genentech USA, Inc. | 9 | $217 |
| Grifols USA, LLC | 7 | $181 |
| Amgen Inc. | 8 | $156 |
| Lilly USA, LLC | 5 | $134 |
Products named: FASENRA, DUPIXENT, Xolair, AIRSUPRA, TEZSPIRE, Hizentra, Prolastin-C Liquid, EBGLYSS.
Industry payments across MA — which companies pay providers there.
